Literature DB >> 11159585

Authors' reply on aspirin for primary prevention.

T W Meade , P J Brennan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159585      PMCID: PMC1119424     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis.

Authors:  L E Ramsay; P S Sanmuganathan; E J Wallis; P R Jackson
Journal:  BMJ       Date:  2000-12-09

2.  Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.

Authors:  T W Meade; P J Brennan
Journal:  BMJ       Date:  2000-07-01

3.  British Hypertension Society guidelines for hypertension management 1999: summary.

Authors:  L E Ramsay; B Williams; G D Johnston; G A MacGregor; L Poston; J F Potter; N R Poulter; G Russell
Journal:  BMJ       Date:  1999-09-04

4.  An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.

Authors:  P R Hebert; C H Hennekens
Journal:  Arch Intern Med       Date:  2000-11-13

5.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

6.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.